Clinical trial infrastructure wasn't designed as a system. It was assembled over 30 years by vendors solving isolated problems with no shared blueprint. Today, sites and sponsors operate across disconnected CTMS, EDC, RTSM, eTMF, and ePRO platforms that require constant manual reconciliation. The cost is real: Phase III trials now run at $55,716 per day in direct operating costs, and 76% of protocols require at least one amendment, up from 57% in 2015. Each substantial Phase III amendment carries a median cost of $535,000, excluding site retraining, IRB cycles, and enrollment disruption. Many amendments trace back to protocol design errors that better-connected systems would have caught earlier. The next generation of platforms treats the protocol as infrastructure. Using standards like CDISC USDM and ICH M11 CeSHarP, a protocol authored once in machine-readable format can flow automatically to EDC, CTMS, and eligibility tools without manual transcription. That shift from document-centric to data-driven execution is what the emerging category of clinical trial operating systems aims to deliver: a single environment where protocol design, site activation, data capture, and regulatory document generation share a common data model.